Vutrisiran: How Can RNA Treat Cardiac Amyloidosis?

What does the nucleic acid market forecast mean for treatment?

Growing interest in nucleic acid medicines extends beyond mRNA vaccines. The IndexBox outlook identifies oligonucleotide treatments, which use short strands of genetic material, among the drivers of demand for pharmaceutical ingredients. Its projections describe an industrial opportunity; they cannot establish that an experimental medicine works or that treatment will become more affordable. Vutrisiran provides a useful clinical example of this broader field, although the forecast does not establish its individual contribution to market growth. [IndexBox market outlook](https://www.indexbox.io/blog/nucleic-acid-raw-materials-market-forecast-to-2035-growth-accelerates-on-mrna-vaccine-and-gene-therapy-demand/)

Transthyretin amyloid cardiomyopathy, or ATTR-CM, develops when deposits of the protein transthyretin accumulate in the heart. Disease can occur with an inherited TTR gene variant or with the usual protein sequence, known as wild-type disease. The liver produces most circulating transthyretin, making it a treatment target even though the major damage occurs elsewhere. [MedlinePlus Genetics](https://medlineplus.gov/genetics/gene/ttr/)

Vutrisiran uses small interfering RNA to promote breakdown of the messenger RNA needed to make transthyretin. This reduces production of the protein. It acts on an RNA message without permanently editing the patient's DNA. [US prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db0facb-81b6-4006-9239-27dc6409c5d3)

What did the HELIOS-B trial show about vutrisiran?

The double-blind HELIOS-B trial randomly assigned 655 adults with ATTR-CM to vutrisiran or placebo. For the primary outcome combining death from any cause with recurrent cardiovascular events, the overall hazard ratio was 0.72, with a 95% confidence interval of 0.56 to 0.93. This corresponds to a 28% relative reduction in the trial's combined endpoint; it does not mean 28 fewer deaths per 100 patients. The findings were published online in 2024 and appeared in a 2025 issue of the New England Journal of Medicine. [HELIOS-B results](https://www.nejm.org/doi/abs/10.1056/NEJMoa2409134)

Participants receiving vutrisiran also experienced less deterioration in walking capacity and a heart-failure health-status score. Some participants were already taking tafamidis, and the trial was not a direct comparison between the two medicines. Alnylam Pharmaceuticals funded the study. These findings support a disease-modifying benefit, while leaving treatment selection dependent on the patient's circumstances. [HELIOS-B trial report](https://www.nejm.org/doi/abs/10.1056/NEJMoa2409134)

Who can receive vutrisiran, and what monitoring matters?

The FDA expanded the US indication for vutrisiran, sold as Amvuttra, in March 2025 to include ATTR-CM. The prescribed dose is 25 mg injected under the skin every three months by a healthcare professional. Treatment lowers blood vitamin A levels, so the US label advises supplementation at the recommended daily allowance. Eye symptoms suggesting vitamin A deficiency require ophthalmology assessment. Patients should discuss supplementation with their treating clinician. [US prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db0facb-81b6-4006-9239-27dc6409c5d3)

Expectations also matter. In a September 2025 letter addressing promotional claims, the FDA emphasized that the evidence did not support suggestions that treatment could return patients to their condition before diagnosis or broadly remove the burdens of ATTR-CM. Slower deterioration can be clinically valuable, but it should not be presented as restoration of normal heart function. For patients interpreting headlines about expanding RNA medicine markets, the relevant questions remain the demonstrated benefits, treatment risks, and suitability for their diagnosed condition. [FDA assessment of Amvuttra promotional claims](https://www.fda.gov/media/188686/download)